Calluna Pharma logo

Calluna Pharma

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.

27 employees · est. 2024 · Oslo, Norway

VS
Yuanyin Bio logo

Yuanyin Bio

Pioneering the future of medicine with groundbreaking RNA technology to tackle unmet clinical needs and develop novel preventive and therapeutic solutions.

est. 2021

Yuanyin Bio is the older company (2024 vs 2021).

Side-by-Side Comparison

Calluna Pharma Yuanyin Bio
Founded
2024 2021 older
Headquarters
Oslo, Norway Not tracked yet
Employees
27 Not tracked yet
Industry
Biotechnology, Pharmaceutical Biopharma, Biotechnology, Pharmaceutical
Funding Stage
Series A Series A
Total Funding
$75.00M $142.00M
Funding Rounds
1 2
Services
development of first-in-class clinical-stage antibodies, research and development in fibrosis and inflammation, pharmaceutical innovation Development of new pharmaceutical products, Research and application of circular RNA technology, Creation of therapeutic and preventive medicines
Target Customers
patients with high unmet medical needs related to fibrosis and inflammation, healthcare providers, medical institutions Healthcare providers, Pharmaceutical companies, Medical research institutions, Biotechnology developers
Taxonomy
Chronic Inflammation, Fibrosis, Therapies, Clinical Stage, Biotech, Upstream Amplifiers, Immunology, Patient Outcomes, Selective Antibodies, Immunological Diseases, Novel Therapeutics, Unmet Clinical Needs, Disease Spectrum, Therapeutic Pipeline, Biopharmaceutical Innovation RNA Technology, Circular RNA, Innovative Drugs, Therapeutic Solutions, Preventive Medicine, Unmet Clinical Needs, Drug Development, Therapeutics Pipeline, Novel Therapies, Disease Treatment, Medical Innovation, Biopharmaceuticals, Clinical Research, Disease Targeting
Website
callunapharma.com therorna.com
Calluna Pharma logo

About Calluna Pharma

Calluna Pharma, founded in 2024, is a clinical-stage biotech company based in Norway. The company focuses on developing first-in-class therapies to address chronic inflammation and fibrosis by targeting the upstream amplifiers of diseases. This innovative approach could potentially yield treatments...

Yuanyin Bio logo

About Yuanyin Bio

Yuanyin Bio is emerging as a disruptive force in the Biopharma, Biotechnology, and Pharmaceutical sectors with its focus on circular RNA technology. Founded in 2021, the company aims to revolutionize the medical field through its commitment to creating innovative drugs and therapies. The startup is...

We will tell you when either one moves

BounceWatch watches Calluna Pharma and Yuanyin Bio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Calluna Pharma and Yuanyin Bio — by email.

Frequently Asked Questions

Calluna Pharma — Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.. Yuanyin Bio — Pioneering the future of medicine with groundbreaking RNA technology to tackle unmet clinical needs and develop novel preventive and therapeutic solutions.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Calluna Pharma has raised $75.00M while Yuanyin Bio has raised $142.00M.
Calluna Pharma and Yuanyin Bio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Calluna Pharma with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Calluna Pharma on 25 Mar 2026, and Yuanyin Bio on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy